News Agency
Men's Weekly

CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

  • Written by PR Newswire
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for CT071, an...

Read more: CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple...

How Downsizing to a Caravan Can Transform Your Lifestyle

If you’re curious about simplifying life while keeping the sense of adventure, caravan and camping sales offer an inviting gateway. Downsizing to a caravan can transform your daily routine from wrangling a cluttered house every morning to a more manageable... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion